IL9 and cancer: In summary, our findings highlight a promising clinical potential of human IL9-secreting T cells for CAR-T cell immunotherapy for human cancers, attributed to their central memory phenotype and that they are less exhausted, hyperproliferative, and long-lived in vivo.